Company Profile
Evaxion Biotech Stock Price, News & Catalysts
- Ticker:
- EVAX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Denmark
Stock performance
3.16 USD (+0.32%)
Close
Last updated: October 6, 2026
31.3M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, EVAX closed up 0.32% at $3.16. No new same-company headline was identified in the current news window.
Company overview
AI-Enabled Immunotherapy Company
Evaxion Biotech uses computational models to identify antigens and design vaccines for cancer and infectious diseases. Its AI-Immunology platform analyzes immune recognition and prioritizes targets for individualized or off-the-shelf therapies.
EVX-01 Personalized Cancer Vaccine
EVX-01 is a personalized neoantigen vaccine developed for advanced melanoma in combination with checkpoint inhibition. Each treatment is designed from the mutation profile of an individual patient's tumor.
EVX-04 in Acute Myeloid Leukemia
EVX-04 is an off-the-shelf cancer vaccine directed at shared antigens in acute myeloid leukemia. The program is intended to bring the platform into a hematologic cancer without requiring patient-specific manufacturing.
Infectious-Disease Programs
The infectious-disease portfolio includes EVX-B4 for Group A Streptococcus and other vaccine concepts generated through the EDEN and RAVEN platforms. These programs identify bacterial or viral antigens likely to produce protective immune responses.
Partnered Development Model
Evaxion combines internally led programs with collaborations and licensing, including an infectious-disease program licensed to Merck. Partnerships provide validation and may generate research funding, milestones, and royalties.
AI-Immunology Technology Stack
The PIONEER platform identifies cancer neoantigens, while EDEN and RAVEN support bacterial and viral vaccine discovery. Shared computational infrastructure allows Evaxion to generate candidates across multiple disease areas.
Future catalysts
- Presentation of three-year Phase 2 efficacy data for EVX-01 at ESMO 2026.
- Regulatory filing to initiate the first clinical study of EVX-04 in the second half of 2026.
- Preclinical antigen-validation data for EVX-B4 in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Evaxion Biotech (EVAX)?
Evaxion Biotech (EVAX) most recently closed at 3.16 USD, a +0.32% move versus the previous session.
What is the market cap of Evaxion Biotech (EVAX)?
Evaxion Biotech currently has a market capitalization of 31.3M USD on BioPharmSignal.
What does Evaxion Biotech do?
AI-Enabled Immunotherapy Company Evaxion Biotech uses computational models to identify antigens and design vaccines for cancer and infectious diseases. Its AI-Immunology platform analyzes immune recognition and prioritizes targets for individualized or off-the-shelf therapies. EVX-01 Personalized Cancer Vaccine EVX-01 is a personalized neoantigen vaccine...
On which exchange is EVAX stock listed?
Evaxion Biotech (EVAX) is associated with NASDAQ, Denmark, Biopharma.
What is EVX-01?
Presentation of three-year Phase 2 efficacy data for EVX-01 at ESMO 2026.
Which conditions is Evaxion Biotech targeting with EVX-01?
Evaxion Biotech is associated with cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Evaxion Biotech describe recent progress with EVX-01?
Presentation of three-year Phase 2 efficacy data for EVX-01 at ESMO 2026.
What is EVX-04?
EVX-04 in Acute Myeloid Leukemia EVX-04 is an off-the-shelf cancer vaccine directed at shared antigens in acute myeloid leukemia.